Company Analysis ABIOMED
1. Summary
Advantages
- The stock's return over the last year (0%) is higher than the sector average (-12.5%).
- The company's current efficiency (ROE=9.64%) is higher than the sector average (ROE=9.61%)
Disadvantages
- Price (377.5 $) is higher than fair price (35.77 $)
- Dividends (0%) are below the sector average (0.541%).
- Current debt level 0.5976% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| ABIOMED | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 2.5% | 0.6% |
| 90 days | 0% | -17.8% | 2% |
| 1 year | 0% | -12.5% | 23.4% |
ABMD vs Sector: ABIOMED has outperformed the "Healthcare" sector by 12.5% over the past year.
ABMD vs Market: ABIOMED has significantly underperformed the market by -23.4% over the past year.
Stable price: ABMD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ABMD with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (377.5 $) is higher than the fair price (35.77 $).
Price is higher than fair: The current price (377.5 $) is 90.5% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (108.16) is higher than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (108.16) is higher than that of the market as a whole (49.04).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (9.82) is higher than that of the sector as a whole (4.83).
P/BV vs Market: The company's P/BV (9.82) is higher than that of the market as a whole (3.17).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (14.31) is lower than that of the sector as a whole (33.77).
P/S vs Market: The company's P/S indicator (14.31) is higher than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (54.5) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (54.5) is higher than that of the market as a whole (28.32).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -6.55% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-6.55%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (4135.44%).
5.4. ROE
ROE vs Sector: The company's ROE (9.64%) is higher than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (9.64%) is lower than that of the market as a whole (10.71%).
5.5. ROA
ROA vs Sector: The company's ROA (8.62%) is higher than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (8.62%) is higher than that of the market as a whole (6.47%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.12%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (7.12%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.541%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 17.02.2022 | SUTTER MARTIN P Director |
Sale | 314.71 | 1 258 840 | 4 000 |
| 16.02.2022 | SUTTER MARTIN P Director |
Sale | 308.66 | 617 320 | 2 000 |
| 15.02.2022 | SUTTER MARTIN P Director |
Sale | 303.65 | 607 300 | 2 000 |
| 29.12.2020 | Greenfield Andrew J VP, Chief Commercial Officer |
Sale | 321 | 1 605 000 | 5 000 |
| 18.11.2020 | SUTTER MARTIN P Director |
Sale | 268.34 | 201 255 | 750 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
